> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Natera Stock Plunges 12.65% After Earnings — Adjusted Loss Exceeds Forecast Despite Raised Outlook
- URL: https://www.bullished.co/natera-stock-plunges-12-65-after-earnings-adjusted-loss-exceeds-forecast-despite-raised-4a93ce75/
- Published: 2026-11-06T14:55:03.000Z
- Updated: 2026-11-06T14:55:03.000Z
- Description: Natera lifted its revenue outlook and appointed Solomon Moshkevich CEO, with a plan to double sales.
- Author: Matteo Parrino
- Tags: Markets, NTRA, Industry: Healthcare

[Natera](https://www.bullished.co/tag/ntra/), which runs blood-based genetic tests for cancer, women's health and organ health, plunged 12.65% to $317.73 in Friday trading, as of 9:52 a.m. ET, erasing $6.6 billion in market value after earnings and a CEO change. The third-quarter adjusted loss [exceeded the forecast](https://www.marketwatch.com/story/natera-shares-slide-on-wider-than-expected-loss-ceo-transition-26e81bbf?ref=bullished.co) even though the company raised its revenue outlook.

## A Smaller Loss Still Misses

Natera's adjusted loss came to [$0.39 per share](https://finance.yahoo.com/markets/stocks/articles/natera-ntra-reports-q3-loss-000018878.html?.tsrc=rss&ref=bullished.co) for the quarter. Zacks Equity Research had [anticipated a loss](https://www.zacks.com/stock/news/3025043/natera-ntra-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental%5Fanalysis|yseop%5Ftemplate%5F4-3025043&ref=bullished.co) of $0.17 per share; the year-earlier adjusted loss was $0.64 per share.

The revenue outlook moved in the opposite direction: Natera now [expects $3.01 billion](https://www.marketwatch.com/story/natera-shares-slide-on-wider-than-expected-loss-ceo-transition-26e81bbf?ref=bullished.co) to $3.04 billion, compared with its previous range of $2.85 billion to $2.91 billion.

Thursday's earnings release accompanied the appointment of Solomon Moshkevich as CEO, replacing Steve Chapman, according to the company's [SEC filing](https://www.sec.gov/Archives/edgar/data/0001604821/000160482126000032/ntra-20261105.htm?ref=bullished.co). Chapman remains a consultant and adviser to the board.

## A Sharp Retreat From Yearly Gains

NTRA shares were on pace for their biggest one-day decline in at least 275 trading sessions in Friday trading, as of 9:52 a.m. ET. Natera's market value stood at $45.8 billion at that same point in Friday trading.

The stock entered the session with a sizable lead over the wider market. At Thursday's close, Natera was up 59% year-to-date against an 8% gain for the S&P 500, though its shares had fallen 15% over the previous month through Thursday's close.

## Moshkevich's Sales-Doubling Plan

On Thursday's earnings call, Moshkevich outlined a [plan to double](https://nz.finance.yahoo.com/news/natera-inc-ntra-q3-2026-052728300.html?ref=bullished.co) sales, with early cancer screening contributing barely anything to the target.

Natera's existing tests span several uses. Signatera monitors cancer remaining after treatment; Panorama is a prenatal test. The company also offers carrier and hereditary cancer screening, tests for rejection of kidney, heart and lung transplants, and genetic testing for chronic kidney disease.

The Austin, Texas-based company processed about 3.5 million tests in 2025 and reported $2,306.1 million in revenue that year. Its own U.S. sales team and more than 100 laboratory and distribution partners sell its products, which are offered in more than 80 countries.

Natera expects positive free cash flow—cash left after capital spending—in the fourth quarter, according to its [earnings-call update](https://nz.finance.yahoo.com/news/natera-inc-ntra-q3-2026-052728300.html?ref=bullished.co).

### Sources

- [Natera Shares Slide on Wider-Than-Expected Loss, CEO Transition](https://www.marketwatch.com/story/natera-shares-slide-on-wider-than-expected-loss-ceo-transition-26e81bbf?ref=bullished.co) — MarketWatch
- [Natera stock falls on Q3 results, CEO exit (NTRA:NASDAQ)](https://seekingalpha.com/news/4668067-natera-stock-falls-q3-results-ceo-exit?ref=bullished.co) — seekingalpha.com
- [Natera Inc (NTRA) Q3 2026 Earnings Call Highlights: Revenue Jumps 34% as Guidance Raised Above ...](https://nz.finance.yahoo.com/news/natera-inc-ntra-q3-2026-052728300.html?ref=bullished.co) — Yahoo Finance
- [Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates](https://finance.yahoo.com/markets/stocks/articles/natera-ntra-reports-q3-loss-000018878.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Natera: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/natera-q3-earnings-snapshot-222342987.html?ref=bullished.co) — Associated Press
- [NTRA 8-K: On November 5, 2026, Natera, Inc. issued a press release announcing the results for its third quarter ended September 30, 2026 and provided a related investor presentation](https://www.sec.gov/Archives/edgar/data/0001604821/000160482126000032/ntra-20261105.htm?ref=bullished.co) — SEC 8-K Filing
- [Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3025043/natera-ntra-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental%5Fanalysis|yseop%5Ftemplate%5F4-3025043&ref=bullished.co) — Zacks Investment Research
- [Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates](https://www.zacks.com/stock/news/3023514/caris-life-sciences-inc-cai-q3-earnings-and-revenues-top-estimates?cid=CS-ZC-FT-fundamental%5Fanalysis|yseop%5Ftemplate%5F4-3023514&ref=bullished.co) — Zacks Investment Research
- [Natera — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1604821/000162828026071145/ntra-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Natera

- [Natera Sets $6 Billion Revenue Goal For 2029 As Moshkevich Replaces Chapman As CEO](https://www.bullished.co/natera-sets-6-billion-revenue-goal-for-2029-as-moshkevich-replaces-chapman-as-ceo-7bae9c7d/)
- [Natera's Revenue True-Ups Fall To $32.3 Million As Its CEO Resigns](https://www.bullished.co/nateras-revenue-true-ups-fall-to-32-3-million-as-its-ceo-resigns-94185198/)
- [Fidelity Parent FMR Reports 9.5% Passive Stake In Natera](https://www.bullished.co/fidelity-parent-fmr-reports-9-5-passive-stake-in-natera-5d9dd90c/)

[All Natera (NTRA) coverage →](https://www.bullished.co/tag/ntra/)